慢性阻塞性肺疾病患者血清胞浆型磷脂酶A2α基因和表达水平检测的临床意义

Clinical Significant of Detecting the Cytoplasm of Phospholipase A2αExpression in Patints with Chronic Obstructive Pulmonary Disease

目的：探讨慢性阻塞性肺疾病（COPD）患者检测胞浆型磷脂酶 cPLA2α（cPLA2α）基因表达水平的临床意义。方法选取收治的 COPD 患者90例，按照 COPD 严重程度分级标准分为轻度组30例，中度组35例和重度组25例，以同期90例肺功能正常的健康体检者为对照组。用酶联免疫吸附试验（ELISA）检测受试者血清中 cPLA2α含量，同时用逆转录聚合酶链式反应（RT-PCR）检测同组患者 cPLA2α基因表达水平。结果 COPD 轻度组 cPLA2α的含量为（0.0392±0.0051）pg／ml，表达为（0.68±0.01）；中度组含量为（0.049 8±0.0074）pg／ml，表 达为（0.92±0.02）；重度组含量为（0.0554±0.0081）pg／ml，表达为（1.35±0.02）；而对照组含量为（0.0102±0.0066）pg／ml，表达为（0.11±0.01）。无论是 cPLA2α血清学水平还是基因表达水平，四组之间差异均有统计学意义（F ＝8.643，12.415，P ＜0.05）。且 COPD 各组随着病变程度加重 cPLA2α的水平逐渐增加，且三组彼此比较差异有统计学意义（t＝3.013～5.817，5.039～11.667，P 均＜0.05）。结论血 cPLA2α水平可预示 COPD 严重程度，cPLA2α是诊疗 COPD 及分级的新靶标。

Objective To discuss the clinical significant of detecting cytoplasm phospholipase A2 alpha （cPLA2α）in patients with chronic obstructive pulmonary disease （COPD）.Methods Selected treated 90 cases of patients with COPD.According to the COPD severity classification standard,they were divided into mild group of 30 cases,moderate group of 25 cases and severe group of 35 cases.In the same period of physical examination,90 cases of normal lung function healthy were control group.Used Enzyme linked immunosorbent test （ELISA）to detect cPLA2αlevel of these groups.At the same time,detected cPLA2αexpression of these groups by RT-PCR.Results cPLA2αlevel in serum of mild group was （0.039 2±0.005 1）pg/ml,gene expression was （0.68±0.01）,in moderate group （0.049 8±0.007 4）pg/ml and （0.92±0.02）,in severe group （0.055 4±0.008 1）and （1.35±0.02）.and in Healthy controls group （0.010 2±0.006 6）pg/ml and （0.11±0.01）.There were significant differences among four groups （t = 3.013 - 5.817,5.039 - 11.667,P 《0.05）.Conclusion Detection of blood cPLA2αcan indicate COPD severity,and cPLA2α is the new molecular targets of diagnosis,treatment and classifica-tion COPD.